a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10617909		
Filing Date		2003-07-11		
First Named Inventor	Richa	ard P. Mousseau		
Art Unit		2194		
Examiner Name	Diem	K. Cao		
Attorney Docket Number		BEAS-01076US1		

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	7100195		2006-08-29	Underwood	
	2	5805798		1998-09-08	Keams et al.	
	3 5163148			1992-11-10	Walls	
	4	6963857		2005-11-08	Johnson	
	5	6212521		2001-04-03	Minami et al.	
	6	6779017		2004-08-17	Lamberton et al.	
	7	4714996		1987-12-22	Gladney et al.	
f you wish	n to a	dd additional U.S. Pa	tent citatio	n information p	lease click the Add button.	Add

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10617909	
iling Date		2003-07-11	
irst Named Inventor	Richard P. Mousseau		
Art Unit		2194	
xaminer Name Diem		K. Cao	
Attorney Docket Number		BEAS-01076US1	

Examiner Initial*	Cite No Publication Number		Kind Code ¹	Publication Date		Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	20020161839		2002-10	i-31	Colasurdo et a	al.				
If you wisl	h to a	dd additional U.S. Publ	shed Ap	plication	citatio	n information p	please click the Ad	d butto	n. Add		
				FOREIG	SN PAT	TENT DOCUM	IENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j		Kind Publication	Name of Patentee or Applicant of cited Document		Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		TS	
	1										
If you wisl	h to a	dd additional Foreign P	atent Do	cument	citation	information p	lease click the Add	buttor	Add		
			NO	I-PATE	T LITE	RATURE DO	CUMENTS		Remove		
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the ar					Τs						
	VISVESWARAN, SIVA, "Dive into connection pooling with JZEE", http://java.sun.com/developer/technicalarticles/ JZEE/pooling/index.html. Reprinted from JavaWorld. October 2000. pages 1-7.										

Examiner Signature | Date Considered |

Examiner Signature | Date Considered |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include cook of this form with next communication to associant.

If you wish to add additional non-patent literature document citation information please click the Add button Add

1 See Kind Codes of USPTID Patient Documents at sever_USPTID_CODY or MRCP 901.04. ² Earlier office that issued the document, by the Nov-Midt code (WIPD Standard ST.3). ² Sort Juspance patient Contaments, but notices not be year of the Proprior many procedure or serial number of the patient contament, if Nort of Countered by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if Emploit binocause translation is attacked.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10617909	
Filing Date		2003-07-11	
First Named Inventor	Richa	rd P. Mousseau	
Art Unit		2194	
Examiner Name	Diem	K. Cao	
Attorney Docket Number		BEAS-01076US1	

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	d 1.98 to make the appropriate selection(s):
---------------	--------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- _ ...

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Sheldon R. Meyer/	Date (YYYY-MM-DD)	2007-06-04
Name/Print	Sheiring R Meyer	Registration Number	27660

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.